Αποτελέσματα αναζήτησης - "периферический атеросклероз"

1

Academic Journal

The role of acetylsalicylic acid in the treatment of diseases caused by atherosclerosis ; Место ацетилсалициловой кислоты в лечении заболеваний, вызванных атеросклерозом

Συγγραφείς: I. S. Yavelov, И. С. Явелов

Πηγή: Aterotromboz = Atherothrombosis; Том 13, № 1 (2023); 23-34 ; Атеротромбоз; Том 13, № 1 (2023); 23-34 ; 2658-5952 ; 2307-1109 ; 10.21518/2307-1109-2023-1

Θεματικοί όροι: ишемический инсульт, coronary heart disease, acute coronary syndrome, peripheral atherosclerosis, ischemic stroke, коронарная болезнь сердца, острый коронарный синдром, периферический атеросклероз

Περιγραφή αρχείου: application/pdf

Relation: https://www.aterotromboz.ru/jour/article/view/299/304; Naim C., Douziech M., Therasse E., Robillard P., Giroux M.F., Arsenault F. et al. Vulnerable atherosclerotic carotid plaque evaluation by ultrasound, computed tomography angiography, and magnetic resonance imaging: an overview. Can Assoc Radiol J. 2014;65(3):275–286. https://doi.org/10.1016/j.carj.2013.05.003.; Vergallo R., Crea F. Atherosclerotic Plaque Healing. N Engl J Med. 2020;383(9):846–857. https://doi.org/10.1056/NEJMra2000317.; Vergallo R., Porto I., D’Amario D., Annibali G., Galli M., Benenati S. et al. Coronary Atherosclerotic Phenotype and Plaque Healing in Patients With Recurrent Acute Coronary Syndromes Compared With Patients With Longterm Clinical Stability: An In Vivo Optical Coherence Tomography Study. JAMA Cardiol. 2019;4(4):321–329. https://doi.org/10.1001/jamacardio.2019.0275.; Kopczak A., Schindler A., Bayer-Karpinska A., Koch M.L., Sepp D., Zeller J. et al. Complicated Carotid Artery Plaques as a Cause of Cryptogenic Stroke. J Am Coll Cardiol. 2020;76(19):2212–2222. https://doi.org/10.1016/j.jacc.2020.09.532.; Baigent C., Blackwell L., Collins R., Emberson J., Godwin J., Peto R. et al. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet. 2009;373(9678):1849–1860. https://doi.org/10.1016/S0140-6736(09)60503-1.; Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ. 2002;324(7329):71–86. https://doi.org/10.1136/bmj.324.7329.71.; Sundström J., Hedberg J., Thuresson M., Aarskog P., Johannesen K.M., Oldgren J. Low-Dose Aspirin Discontinuation and Risk of Cardiovascular Events: A Swedish Nationwide, Population-Based Cohort Study. Circulation. 2017;136(13):1183–1192. https://doi.org/10.1161/CIRCULATIONAHA.117.028321.; Knuuti J., Wijns W., Saraste A., Capodanno D., Barbato E., Funck-Brentano C. et al. 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes. Eur Heart J. 2020;41(3):407–477. https://doi.org/10.1093/eurheartj/ehz425.; Барбараш О.Л., Карпов Ю.А., Кашталап В.В., Бощенко А.А., Руда М.М., Акчурин Р.С. и др. Стабильная ишемическая болезнь сердца. Клинические рекомендации 2020. Российский кардиологический журнал. 2020;(11):4076. https://doi.org/10.15829/29/1560-4071-2020-4076.; Bonaca M.P., Bhatt D.L., Cohen M., Steg P.G., Storey R.F., Jensen E.C. et al. Long-term use of ticagrelor in patients with prior myocardial infarction. N Engl J Med. 2015;372(19):1791–1800. https://doi.org/10.1056/NEJMoa1500857.; Eikelboom J.W., Connolly S.J., Bosch J., Dagenais G.R., Hart R.G., Shestakovska O. et al., Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease. N Engl J Med. 2017;377(14):1319–1330. https://doi.org/10.1056/NEJMoa1709118.; Visseren F.L.J., Mach F., Smulders Y.M., Carballo D., Koskinas K.C., Bäck M. et al. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J. 2021;42(34):3227–3337. https://doi.org/10.1093/eurheartj/ehab484.; Steg P.G., Bhatt D.L., Simon T., Fox K., Mehta S.R., Harrington R.A. et al. Ticagrelor in Patients with Stable Coronary Disease and Diabetes. N Engl J Med. 2019;381(14):1309–1320. https://doi.org/10.1056/NEJMoa1908077.; Collet J.P., Thiele H., Barbato E., Barthélémy O., Bauersachs J., Bhatt D.L. et al. 2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J. 2021;42(14):1289–1367. https://doi.org/10.1093/eurheartj/ehaa575.; Sibbing D., Aradi D., Jacobshagen C., Gross L., Trenk D., Geisler T. et al. Guided de-escalation of antiplatelet treatment in patients with acute coronary syndrome undergoing percutaneous coronary intervention (TROPICAL-ACS): a randomised, open-label, multicentre trial. Lancet. 2017;390(10104):1747–1757. https://doi.org/10.1016/S0140-6736(17)32155-4.; Claassens D.M.F., Vos G.J.A., Bergmeijer T.O., Hermanides R.S., van ‘t Hof A.W.J., van der Harst P. et al. A Genotype-Guided Strategy for Oral P2Y12 Inhibitors in Primary PCI. N Engl J Med. 2019;381(17):1621–1631. https://doi.org/10.1056/NEJMoa1907096.; Kim C.J., Park M.W., Kim M.C., Choo E.H., Hwang B.H., Lee K.Y. et al. Unguided de-escalation from ticagrelor to clopidogrel in stabilised patients with acute myocardial infarction undergoing percutaneous coronary intervention (TALOS-AMI): an investigator-initiated, open-label, multicentre, non-inferiority, randomised trial. Lancet. 2021;398(10308):1305–1316. https://doi.org/10.1016/S0140-6736(21)01445-8.; Bianco M., Careggio A., Destefanis P., Luciano A., Perrelli M.G., Quadri G. et al. P2Y12 inhibitors monotherapy after short course of dual antiplatelet therapy in patients undergoing percutaneous coronary intervention: a meta-analysis of randomized clinical trials including 29 089 patients. Eur Heart J Cardiovasc Pharmacother. 2021;7(3):196–205. https://doi.org/10.1093/ehjcvp/pvaa038.; Hong S.J., Ahn C.M., Kim J.S., Kim B.K., Ko Y.G., Choi D. et al. Effect of ticagrelor monotherapy on mortality after percutaneous coronary intervention: a systematic review and meta-analysis of randomized trials including 26 143 patients. Eur Heart J Cardiovasc Pharmacother. 2022;8(1):48–55. https://doi.org/10.1093/ehjcvp/pvaa119.; Mehran R., Baber U., Sharma S.K., Cohen D.J., Angiolillo D.J., Briguori C. et al. Ticagrelor with or without Aspirin in High-Risk Patients after PCI. N Engl J Med. 2019;381(21):2032–2042. https://doi.org/10.1056/NEJMoa1908419.; Hahn J.Y., Song Y.B., Oh J.H., Cho D.K., Lee J.B., Doh J.H. et al. 6-month versus 12-month or longer dual antiplatelet therapy after percutaneous coronary intervention in patients with acute coronary syndrome (SMART-DATE): a randomised, open-label, non-inferiority trial. Lancet. 2018;391(10127):1274–1284. https://doi.org/10.1016/S0140-6736(18)30493-8.; Watanabe H., Morimoto T., Natsuaki M., Yamamoto K., Obayashi Y., Ogita M. et al. Comparison of Clopidogrel Monotherapy After 1 to 2 Months of Dual Antiplatelet Therapy With 12 Months of Dual Antiplatelet Therapy in Patients With Acute Coronary Syndrome: The STOPDAPT-2 ACS Randomized Clinical Trial. JAMA Cardiol. 2022;7(4):407–417. https://doi.org/10.1001/jamacardio.2021.5244.; Hindricks G., Potpara T., Dagres N., Arbelo E., Bax J.J., Blomström-Lundqvist C. et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): The Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. Eur Heart J. 2021;42(5):373–498. https://doi.org/10.1093/eurheartj/ehaa612.; Steffel J., Collins R., Antz M., Cornu P., Desteghe L., Haeusler K.G. et al. 2021 European Heart Rhythm Association Practical Guide on the Use of Non-Vitamin K Antagonist Oral Anticoagulants in Patients with Atrial Fibrillation. Europace. 2021;23(10):1612–1676. https://doi.org/10.1093/europace/euab065.; Aboyans V., Bauersachs R., Mazzolai L., Brodmann M., Palomares J.F.R., Debus S. et al. Antithrombotic therapies in aortic and peripheral arterial diseases in 2021: a consensus document from the ESC working group on aorta and peripheral vascular diseases, the ESC working group on thrombosis, and the ESC working group on cardiovascular pharmacotherapy. Eur Heart J. 2021;42(39):4013–4024. https://doi.org/10.1093/eurheartj/ehab390.; Belch J., MacCuish A., Campbell I., Cobbe S., Taylor R., Prescott R. et al. The prevention of progression of arterial disease and diabetes (POPADAD) trial: factorial randomised placebo controlled trial of aspirin and antioxidants in patients with diabetes and asymptomatic peripheral arterial disease. BMJ. 2008;337:a1840. https://doi.org/10.1136/bmj.a1840; Aboyans V., Ricco J.B., Bartelink M.E.L., Björck M., Brodmann M., Cohnert T. et al. 2017 ESC Guidelines on the Diagnosis and Treatment of Peripheral Arterial Diseases, in collaboration with the European Society for Vascular Surgery (ESVS): Document covering atherosclerotic disease of extracranial carotid and vertebral, mesenteric, renal, upper and lower extremity arteries Endorsed by: the European Stroke Organization (ESO) The Task Force for the Diagnosis and Treatment of Peripheral Arterial Diseases of the European Society of Cardiology (ESC) and of the European Society for Vascular Surgery (ESVS). Eur Heart J. 2018;39(9):763–816. https://doi.org/10.1093/eurheartj/ehx095.; CAST: randomised placebo-controlled trial of early aspirin use in 20,000 patients with acute ischaemic stroke. CAST (Chinese Acute Stroke Trial) Collaborative Group. Lancet. 1997;349(9066):1641–1649. Available at: https://pubmed.ncbi.nlm.nih.gov/9186381.; https://www.aterotromboz.ru/jour/article/view/299

Διαθεσιμότητα: https://www.aterotromboz.ru/jour/article/view/299
https://doi.org/10.21518/at2023-003

View record from BASE

2

Academic Journal

Features of Prediction of Heart Failure in Patients with Peripheral Atherosclerosis During a Three-Year Prospective Follow-Up ; ОСОБЕННОСТИ ПРОГНОЗИРОВАНИЯ СЕРДЕЧНОЙ НЕДОСТАТОЧНОСТИ У ПАЦИЕНТОВ С ПЕРИФЕРИЧЕСКИМ АТЕРОСКЛЕРОЗОМ В ТЕЧЕНИЕ ТРЕХЛЕТНЕГО ПРОСПЕКТИВНОГО НАБЛЮДЕНИЯ

Συγγραφείς: N. D. Kobzeva, V. P. Terentev, V. D. Oleinikova, Н. Д. Кобзева, В. П. Терентьев, В. Д. Олейникова

Πηγή: The Russian Archives of Internal Medicine; Том 12, № 5 (2022); 380-388 ; Архивъ внутренней медицины; Том 12, № 5 (2022); 380-388 ; 2411-6564 ; 2226-6704

Θεματικοί όροι: атеросклероз сонных артерий, peripheral atherosclerosis, renal atherosclerosis, carotid atherosclerosis, периферический атеросклероз, атеросклероз почечных артерий

Περιγραφή αρχείου: application/pdf

Relation: https://www.medarhive.ru/jour/article/view/1510/1159; https://www.medarhive.ru/jour/article/view/1510/1168; Барбараш, О.Л, Семенов В.Ю., Самородская И.В. Коморбидная патология у пациентов ишемической болезнью при коронарном шунтировании: опыт двух кардиохирургических центров. Россий ский кардиологический журнал. 2017; 3(143):6-13. DOI:10.15829/1560-4071-2017-3-6-13; Агеев, Ф.Т. Овчинников А.Г. Сердечная недостаточность с промежуточной фракцией выброса левого желудочка: существует ли клиническая необходимость выделения ее в отдельную подгруппу? Кардиология. 2018.; 58(12 S):4-10. DOI:10.18087/cardio.2609; Бойцов, С.А., Демкина А.Е., Ощепкова Е.В. и др. Достижения и проблемы практической кардиологии в России на современном этапе. Кардиология. 2019; 59(3): 53-59. DOI:10.18087/cardio.2019.3.10242; Гаврюшина, С.В., Агеев Ф.Т. Сердечная недостаточность с сохраненной фракцией выброса левого желудочка: эпидемиология, «портрет» пациента, клиника, диагностика. Кардиология. 2018; 58 (S4): 55-64. DOI:10.18087/cardio.2467; Kobzeva ND, Terentev VP., Zolotuhina I.Ways to optimize the prediction of vascular events in patients with acute coronary syndrome and atherosclerotic lesions of the renal arteries. IOP Conference Series Materials Science and Engineering. 2019; 680(1): 012046. 333-340. DOI:10.1088/1757-899X/680/1/012046; Aboyans V, Ricco JB, Bartelink MEL et al. ESC Scientific Document Group. 2017 ESC Guidelines on the Diagnosis and Treatment of Peripheral Arterial Diseases, in collaboration with the European Society for Vascular Surgery (ESVS): Document covering atherosclerotic disease of extracranial carotid and vertebral, mesenteric, renal, upper and lower extremity arteries. Endorsed by: the European Stroke Organization (ESO)The Task Force for the Diagnosis and Treatment of Peripheral Arterial Diseases of the European Society of Cardiology (ESC) and of the European Society for Vascular Surgery (ESVS). Eur Heart J. 2018; 39(9): 763-816. DOI:10.1093/eurheartj/ehx095; Mancia G, Fagard R, Narkiewicz K, et al. 2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J. 2013; 34(28): 2159-219. DOI:10.1093/eurheartj/eht151; Мареев В.Ю., Фомин И.В., Агеев Ф.Т., и др. Клинические рекомендации. Хроническая сердечная недостаточность (ХСН). Журнал Сердечная Недостаточность. 2017; 18(1): 3–40. doi: DOI:10.18087/cardio.2475; Alagoz AN, Acar BA, Acar T, et al. Relationship Between Carotid Stenosis and Infarct Volume in Ischemic Stroke Patients. Med Sci Monit. 201616(22):4954-4959. DOI:10.12659/msm.898112.; Knappich C, Kuehn l A, Haller B, et al. Associations of Perioperative Variables With the 30-Day Risk of Stroke or Death in Carotid Endarterectomy for Symptomatic Carotid Stenosis. Stroke. 2019. 50(12): 439-3448. DOI:10.1161/STROKEAHA.119.026320.; Кобзева Н.Д. Особенности влияния атеросклеротического поражения различных сосудистых бассейнов на риск развития фатальных и нефатальных событий в отдаленном периоде. Терапия. 2021; 8: 70–75. doi: DOI:10.18565/therapy.2021.8.70-75; Ameri P., Schiattarella G., Crotti L., et al. Novel Basic Science Insights to Improve the Management of Heart Failure: Review of the WorkingGroup on Cellular and Molecular Biology of the Heart of the Italian Society of Cardiology .International journal of molecular sciences. 2020. 1192:1 — 17. DOI:10.3390/ijms21041192.; van Bilsen M, Patel HC, Bauersachs J, et al. The autonomic nervous system as a therapeutic target in heart failure: a scientific position statement from the Translational Research Committee of the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail. 2017;19(11):1361-1378. DOI:10.1002/ejhf.921; Redfield MM. Heart Failure with Preserved Ejection Fraction. N Engl J Med. 2016. 375(19): 1868-1877. DOI:10.1056/NEJMcp1511175; Dunlay SM, Roger VL, Redfield MM. Epidemiology of heart failure with preserved ejection fraction. Nat Rev Cardiol. 2017; 591-602. DOI:10.1038/nrcardio.2017.65; Hubesch G, Hanthazi A, Acheampong A et al. Preclinical Rat Model of Heart Failure With Preserved Ejection Fraction With Multiple Comorbidities. Front Cardiovasc Med. 2022; 8: 809885.1-15. DOI:10.3389/fcvm.2021.809885; Alherbish A, Becher H, Alemayehu W, et al. Impact of contrast echocardiography on accurate discrimination of specific degree of left ventricular systolic dysfunction and comparison with cardiac magnetic resonance imaging. Echocardiography. 2018; 35(11): 1746-1754. DOI:10.1111/echo.14152; Nagueh S, Smiseth O, Appleton C, et al. Recommendations for the evaluation of left ventricular diastolic function by echocardiography: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr. 2016; 277-314. DOI:10.1016/j.echo.2016.01.011; Morris DA, Ma XX, Belyavskiy E, et al. Left ventricularlongitudinal systolic function analysed by 2D speckle-tracking echocardiography in heart failure with preserved ejection fraction: a meta-analysis. Open Heart. 2017; 1-12 DOI:10.1136/openhrt-2017-000630; M, Patrono C, Collet J-P, et al. 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J. 2016;37(3).267-315. DOI:10.1093/eurheartj/ehv320; Becker MAJ, Cornel JH, van de Ven PM, et al. The Prognostic Value of Late Gadolinium-Enhanced Cardiac Magnetic Resonance Imaging in Nonischemic Dilated Cardiomyopathy: A Review and Meta-Analysis. JACC Cardiovasc Imaging. 2018;11(9):1274-1284. DOI:10.1016/j.jcmg.2018.03.006; Zhao Y, Evans MA, Allison MA, et al. Multisite atherosclerosis in subjects with metabolic syndrome and diabetes and relation to cardiovascular events: The Multi-Ethnic Study of Atherosclerosis. Atherosclerosis. 2019; 282: 202-209. DOI:10.1016/j.atherosclerosis.2018.12.005; https://www.medarhive.ru/jour/article/view/1510

Διαθεσιμότητα: https://www.medarhive.ru/jour/article/view/1510
https://doi.org/10.20514/2226-6704-2022-12-5-380-388

View record from BASE

3

Academic Journal

Исследование ассоциации полиморфизма rs10508336 гена транскрипционного фактора TAF3 с риском развития заболеваний артерий нижних конечностей в российской популяции

Συγγραφείς: Жабин, С. Н.

Θεματικοί όροι: медицина, медицинская генетика, периферический атеросклероз нижних конечностей, диабетическая ангиопатия, генетическая предрасположенность, однонуклеотидный полиморфизм, TAF3, курение

Relation: http://dspace.bsu.edu.ru/handle/123456789/51304

Διαθεσιμότητα: http://dspace.bsu.edu.ru/handle/123456789/51304

View record from BASE

4

Academic Journal

Features of manifestation and progression for critical lower limb ischemia in subjects with abdominal aortic calcification: a pilot study

Συγγραφείς: V. A. Zelinskiy, M. V. Melynikov

Πηγή: Патология кровообращения и кардиохирургия, Vol 21, Iss 3, Pp 58-64 (2017)

Θεματικοί όροι: RD1-811, кальциноз брюшной аорты, периферический атеросклероз, критическая ишемия нижних конечностей, разрыв атеросклеротической бляшки, Surgery, 3. Good health

Σύνδεσμος πρόσβασης: http://journalmeshalkin.ru/index.php/heartjournal/article/download/442/428
https://doaj.org/article/e8a51c22c47c4074a1705b8e763db318
https://core.ac.uk/display/132754057
https://doaj.org/article/e8a51c22c47c4074a1705b8e763db318
http://journalmeshalkin.ru/index.php/heartjournal/article/view/442
http://journalmeshalkin.ru/index.php/heartjournal/article/download/442/428

View record at OpenAIRE Full Text Finder

5

Academic Journal

Comparative Study of the Results of a Three-year Observation of Cardiologists and Surgeons in Patients with Peripheral Atherosclerosis ; Сравнительное исследование результатов трехлетнего наблюдения у кардиологов и хирургов пациентов с облитерирующим атеросклерозом нижних конечностей

Συγγραφείς: L. Barbarash S., A. Sumin N., Yu. Medvedeva D., E. Korok V., Л. Барбараш С., А. Сумин Н., Ю. Медведева Д., Е. Корок В.

Πηγή: Rational Pharmacotherapy in Cardiology; Vol 15, No 5 (2019); 690-696 ; Рациональная Фармакотерапия в Кардиологии; Vol 15, No 5 (2019); 690-696 ; 2225-3653 ; 1819-6446

Θεματικοί όροι: peripheral atherosclerosis, outpatient monitoring, optimal medical therapy, периферический атеросклероз, амбулаторное наблюдение, оптимальная медикаментозная терапия

Περιγραφή αρχείου: application/pdf

Relation: https://www.rpcardio.com/jour/article/view/2040/1870; Hussain M.A., Al-Omran M., Mamdani M., et al. Efficacy of a Guideline-Recommended Risk-Reduction Program to Improve Cardiovascular and Limb Outcomes in Patients With Peripheral Arterial Disease. JAMA Surg. 2016;151(8):742-50. DOI:10.1001/jamasurg.2016.0415.; Blinc A., Kozak M., Šabovič M., et al. Survival and event-free survival of patients with peripheral arterial disease undergoing prevention of cardiovascular disease. Int Angiol. 2017;36(3):216-27. DOI:10.23736/S0392-9590.16.03731-7.; O'Donnell T.F.X., Deery S.E., Darling J.D., et al. Adherence to lipid management guidelines is associated with lower mortality and major adverse limb events in patients undergoing revascularization for chronic limb-threatening ischemia. J Vasc Surg. 2017;66(2):572-8. DOI:10.1016/j.jvs.2017.03.416.; Thiney M., Della Schiava N., Ecochard R., et al. Effects on Mortality and Cardiovascular Events of Adherence to Guideline-Recommended Therapy 4 Years after Lower Extremity Arterial Revascularization. Ann Vasc Surg. 2018;52:138-46. DOI:10.1016/j.avsg.2018.03.021.DOI:10.1161/JAHA. 117.005699.; Foley T.R., Singh G.D., Kokkinidis D.G., et al. High-Intensity Statin Therapy Is Associated With Improved Survival in Patients With Peripheral Artery Disease. J Am Heart Assoc. 2017;6(7):e005699. DOI:10. 1161/JAHA.117.005699.; Armstrong E.J., Chen D.C., Westin G.G., et al. Adherence to guideline-recommended therapy is associated with decreased major adverse cardiovascular events and major adverse limb events among patients with peripheral arterial disease. J Am Heart Assoc. 2014;3(2):e000697. DOI:10.1161/JAHA.113.000697.; Chen D.C., Armstrong E.J., Singh G.D., et al. Adherence to guideline-recommended therapies among patients with diverse manifestations of vascular disease. Vasc Health Risk Manag. 2015;11:185-92. DOI:10.2147/VHRM.S76651.; Poredos P., Jezovnik M.K. Do the Effects of Secondary Prevention of Cardiovascular Events in PAD Patients Differ from Other Atherosclerotic Disease? Int J Mol Sci. 2015;16(7):14477-89. DOI:10.3390/ijms160714477.; Berger J.S., Ladapo J.A. Underuse of Prevention and Lifestyle Counseling in Patients With Peripheral Artery Disease. J Am Coll Cardiol. 2017;69(18):2293-300. DOI:10.1016/j.jacc.2017.02.064.; McBride C.L., Akeroyd J.M., Ramsey D.J., et al. Statin prescription rates and their facility-level variation in patients with peripheral artery disease and ischemic cerebrovascular disease: Insights from the Department of Veterans Affairs. Vasc Med. 2018;23(3):232-40. DOI:10.1177/1358863X18758914.; Renard B.M., Seth M., Share D., et al. If not now, when? Prescription of evidence-based medical therapy prior to hospital discharge increases utilization at 6 months in patients with symptomatic peripheral artery disease. Vasc Med. 2015;20(6):544-50. DOI:10.1177/1358863X15599249.; Montminy M.L., Gauvin V., Turcotte S., et al. Factors Influencing the Prescription of Cardiovascular Preventive Therapies in Patients with Peripheral Arterial Disease. PLoS One. 2016;11(2):e0148069. DOI:10.1371/journal.pone.0148069.; Sigvant B., Kragsterman B., Falkenberg M., et al. Contemporary cardiovascular risk and secondary preventive drug treatment patterns in peripheral artery disease patients undergoing revascularization. J Vasc Surg. 2016;64(4):1009-17.e3. DOI:10.1016/j.jvs.2016.03.429.; Thiney M., Della Schiava N., Feugier P., et al. How Admission to a Vascular Surgery Department Improves Medical Treatment in Patients with Lower Extremity Peripheral Arterial Disease. Ann Vasc Surg. 2017;40:85-93. DOI:10.1016/j.avsg.2016.08.030.; Meltzer A.J., Sedrakyan A., Connolly P.H., et al.; Vascular Study Group of Greater. Risk Factors for Suboptimal Utilization of Statins and Antiplatelet Therapy in Patients Undergoing Revascularization for Symptomatic Peripheral Arterial Disease. Ann Vasc Surg. 2018;46:234-40. DOI:10.1016/j.avsg.2017.05.030.; Kumbhani D.J., Steg P.G., Cannon C.P., et al.; REACH Registry Investigators. Statin therapy and longterm adverse limb outcomes in patients with peripheral artery disease: insights from the REACH registry. Eur Heart J. 2014;35(41):2864-72. DOI:10.1093/eurheartj/ehu080.; Arya S., Khakharia A., Binney Z.O., et al. Association of Statin Dose with Amputation and Survival in Patients With Peripheral Artery Disease. Circulation. 2018;137(14):1435-46. DOI:10.1161/CIRCULATIONAHA.117.032361.; Bodewes T.C.F., Darling J.D., O'Donnell T.F.X., et al. Long-term mortality benefit of renin-angiotensin system inhibitors in patients with chronic limb-threatening ischemia undergoing vascular intervention. J Vasc Surg. 2018;67(3):800-8.e1. DOI:10.1016/j.jvs.2017.07.130.; Aboyans V., Ricco J.B., Bartelink M.E.L., et al. ESC Scientific Document Group. 2017 ESC Guidelines on the Diagnosis and Treatment of Peripheral Arterial Diseases. Eur Heart J. 2018;39(9):763-816. DOI:10.1093/eurheartj/ehx095.; Cea-Soriano L., Fowkes F.G.R., Johansson S., et al. Time trends in peripheral artery disease incidence, prevalence and secondary preventive therapy: a cohort study in The Health Improvement Network in the UK. BMJ Open. 2018;8(1):e018184. DOI:10.1136/bmjopen-2017-018184.; Lane R., Harwood A., Watson L., Leng G.C. Exercise for intermittent claudication. Cochrane Database Syst Rev. 2017 Dec 26;12:CD000990. DOI:10.1002/14651858.CD000990.pub4.; Devrome A.N., Aggarwal S., McMurtry M.S., et al. Cardiac rehabilitation in people with peripheral arterial disease: A higher risk population that benefits from completion. Int J Cardiol. 2019;285:108- 14. DOI:10.1002/14651858.CD000990.pub4.; Hageman D., Fokkenrood H.J., Gommans L.N., et al. Supervised exercise therapy versus home-based exercise therapy versus walking advice for intermittent claudication. Cochrane Database Syst Rev. 2018;4:CD005263. DOI:10.1002/14651858.CD005263.pub4.; McDermott M.M., Spring B., Berger J.S., et al. Effect of a Home-Based Exercise Intervention of Wearable Technology and Telephone Coaching on Walking Performance in Peripheral Artery Disease: The HONOR Randomized Clinical Trial. JAMA. 2018;319(16):1665-76. DOI:10.1001/jama.2018.3275.; Сумин А.Н., Косова М.А., Медведева Ю.А. и др. Факторы, влияющие на летальный исход, у пациентов с облитерирующими заболеваниями артерий нижних конечностей. Рациональная Фармакотерапия в Кардиологии. 2017;13(6):746-55. DOI:10.20996/1819-6446-2017-13-6-746-755; https://www.rpcardio.com/jour/article/view/2040

Διαθεσιμότητα: https://www.rpcardio.com/jour/article/view/2040
https://doi.org/10.20996/1819-6446-2019-15-5-690-696

View record from BASE

6

Academic Journal

ОСОБЕННОСТЬ КЛИНИЧЕСКОГО ТЕЧЕНИЯ ПЕРИФЕРИЧЕСКОГО АТЕРОСКЛЕРОЗА В УСЛОВИЯХ ЗАГРЯЗНЕНИЯ ТЕРРИТОРИИ ТЕХНОГЕННЫМИ РАДИОНУКЛИДАМИ

Θεματικοί όροι: contaminated territories, периферический атеросклероз, peripheral atherosclerosis, техногенные радионуклиды, загрязненные территории, 3. Good health, technogenic radionuclides

Σύνδεσμος πρόσβασης: https://cyberleninka.ru/article/n/osobennost-klinicheskogo-techeniya-perifericheskogo-ateroskleroza-v-usloviyah-zagryazneniya-territorii-tehnogennymi-radionuklidami
https://research-journal.org/en/medicine/osobennost-klinicheskogo-techeniya-perifericheskogo-ateroskleroza-v-usloviyax-zagryazneniya-territorii-texnogennymi-radionuklidami/
https://research-journal.org/wp-content/uploads/2018/10/10-2-76.pdf#page=35

7

Academic Journal

IMPACT OF TYPE D PERSONALITY ON PERIPHERAL ARTERY DISEASE INCIDENCE IN PATIENTS WITH CHRONIC LUNG DISEASES ; ВЛИЯНИЕ ТИПА ЛИЧНОСТИ Д НА ЧАСТОТУ ВЫЯВЛЕНИЯ ПЕРИФЕРИЧЕСКОГО АТЕРОСКЛЕРОЗА У БОЛЬНЫХ ХРОНИЧЕСКИМИ ЗАБОЛЕВАНИЯМИ ЛЕГКИХ

Συγγραφείς: A. N. Sumin, E. V. Nedoseykina, O. G. Arkhipov, А. Н. Сумин, Е. В. Недосейкина, О. Г. Архипов

Πηγή: Complex Issues of Cardiovascular Diseases; № 2 (2012); 22-27 ; Комплексные проблемы сердечно-сосудистых заболеваний; № 2 (2012); 22-27 ; 2587-9537 ; 2306-1278 ; 10.17802/2306-1278-2012-2

Θεματικοί όροι: хронические заболевания легких, peripheral atherosclerosis, chronic pulmonary disease, периферический атеросклероз

Relation: Влияние сахарного диабета и психологического дистресса на распространенность атеросклеротического процесса / А. Н. Сумин [и др.] // Кардиология и сердечно-сосудистая хирургия. 2011. № 3. С. 15–21.; Панченко Е. П. По поручению участников регистра REACH в РФ. Результаты трехлетнего наблюдения за амбулаторными больными с клиническими проявлениями атеротромбоза (анализ российской популяции регистра REACH) // Кардиология. 2009. № 10. С. 9–15.; Pedersen S. S., Kupper N., Denollet J. Психологические факторы и заболевания сердца // Болезни сердца и сосудов: руководство Европейского общества кардиологов / под ред. А. Дж. Кэмма, Т. Ф. Люшера, П. В. Серруиса, Е. В. Шляхто. Гл. 35. М.: ГЭОТАР-Медиа, 2011. С. 1332–1352.; Распространенность и клиническая значимость мультифокального атеросклероза у пациентов с инфарктом миокарда и подъемом сегмента ST / Л. С. Барбараш [и др.] // Кардиология и сердечно-сосудистая хирургия. 2010. № 5. С. 31–36.; Сумин А. Н. Поведенческий тип личности Д («дистрессорный») при сердечно-сосудистых заболеваниях // Кардиология. 2010. № 10. С. 66–73.; Тип личности у больных атеросклерозом различной локализации: распространенность и клинические особенности / А. Н. Сумин [и др.] // Клиническая медицина. 2012. № 4. С. 43–49.; Denollet J. DS14: standard assessment of negative affectivity, social inhibition, and Type D personality // Psychosom. Med. 2005. Vol. 67. P. 89–97.; Denollet J., Schiffer A. A., Spek V. A general propensity to psychological distress affects cardiovascular outcomes: evidence from research on the type D (distressed) personality profi le // Circ. Cardiovasc. Qual. Outcomes. 2010. Vol. 3. P. 546–557.; Finkelstein J., Cha E., Scharf S. M. Chronic obstructive pulmonary disease as an independent risk factor for cardiovascular morbidity // Int. J. Chron. Obstruct. Pulmon. Dis. 2009. Vol. 4. P. 337–349.; Health inequalities in the Netherlands: a cross-sectional study of the role of Type D (distressed) personality / M. J. van Bon-Martens [et al.] // BMC Public Health. 2012. Vol. 12. P. 46.; More Evidence that Depressive Symptoms Predict Mortality in COPD Patients: Is Type D Personality an Alternative Explanation? / J. N. de Voogd [et al.] // Аnn. Behav. Med. 2009. Vol. 38. P. 86–93.; Nyklíček I., van Beugen S., Denollet J. Effects of mindfulness-based stress reduction on distressed (Type D) personality traits: a randomized controlled trial // J. Behav. Med. 2012 May 15. [Epub. ahead of print].; The association between anxiety sensitivity and atopy in adult asthmatics / S. Barone [et al.] // J. Behav. Med. 2008. Vol. 31. P. 331–339.; Type D personality and course of health status over 18 months in outpatients with heart failure: multiple mediating inflammatory biomarkers / P. M. Mommersteeg [et al.] // Brain. Behav. Immun. 2012. Vol. 26. P. 301–310.; Type D personality is associated with increased comorbidity burden and health care utilization among 3080 cancer survivors / F. Mols [et al.] // Gen Hosp Psychiatry. 2012. Vol. 34. P. 352–359.; Type D personality, self-effi cacy, and medication adherence following an acute coronary syndrome / G. J. Molloy [et al.] // Psychosom. Med. 2012. Vol. 74. P. 100–106.; Yakubov S. Polyvascular atherosclerotic disease: recognizing the risks and managing the syndrome // Curr. Med. Res. Opin. 2009. Vol. 25. P. 2631–2641.

Διαθεσιμότητα: https://www.nii-kpssz.com/jour/article/view/100
https://doi.org/10.17802/2306-1278-2012-2-22-27

View record from BASE

8

Academic Journal